Jiangsu Historical Income Statement
688670 Stock | 16.68 0.39 2.39% |
Historical analysis of Jiangsu GDK income statement accounts such as Interest Expense of 1.8 M, Selling General Administrative of 95.1 M or Other Operating Expenses of 186.3 M can show how well Jiangsu GDK Biotechnology performed in making a profits. Evaluating Jiangsu GDK income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Jiangsu GDK's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Jiangsu GDK Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jiangsu GDK Biotechnology is a good buy for the upcoming year.
Jiangsu |
About Jiangsu Income Statement Analysis
Jiangsu GDK Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jiangsu GDK shareholders. The income statement also shows Jiangsu investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Jiangsu GDK Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Jiangsu GDK Biotechnology. It is also known as Jiangsu GDK overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Jiangsu GDK's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Jiangsu GDK Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jiangsu GDK Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Jiangsu GDK's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 26.1 M, whereas Depreciation And Amortization is forecasted to decline to about 31.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 9.9M | 1.3M | 1.9M | 1.8M | Depreciation And Amortization | 28.1M | 29.8M | 34.2M | 31.6M |
Jiangsu GDK income statement Correlations
Click cells to compare fundamentals
Jiangsu GDK Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Jiangsu GDK income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 23.3M | 51.3M | 28.1M | 29.8M | 34.2M | 31.6M | |
Interest Expense | 3.0M | 9.6M | 9.9M | 1.3M | 1.9M | 1.8M | |
Selling General Administrative | 7.6M | 24.2M | 12.6M | 13.0M | 90.6M | 95.1M | |
Other Operating Expenses | 92.3M | 351.7M | 249.2M | 240.3M | 276.4M | 186.3M | |
Operating Income | (25.1M) | 211.7M | 150.8M | 95.2M | (40.7M) | (38.7M) | |
Ebit | (25.1M) | 211.7M | 150.8M | 95.2M | 109.4M | 64.1M | |
Research Development | 23.8M | 28.5M | 35.3M | 32.4M | 15.5M | 26.1M | |
Ebitda | (1.8M) | 263.1M | 178.9M | 124.9M | 143.7M | 95.7M | |
Total Operating Expenses | 81.8M | 278.0M | 192.0M | 189.7M | 175.3M | 157.1M | |
Income Before Tax | (31.2M) | 210.9M | 84.0M | 48.4M | (86.6M) | (82.2M) | |
Total Other Income Expense Net | (6.1M) | (812.9K) | (66.8M) | (46.8M) | (42.1M) | (40.0M) | |
Net Income | (19.0M) | 155.0M | 82.5M | 41.5M | (71.0M) | (67.4M) | |
Income Tax Expense | (12.2M) | 55.9M | 1.5M | 6.9M | 7.9M | 4.4M |
Currently Active Assets on Macroaxis
Other Information on Investing in Jiangsu Stock
Jiangsu GDK Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jiangsu GDK shareholders. The income statement also shows Jiangsu investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).